Taxotere Concentrate For Solution For Injection 20Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • Weekly Ad

Taxotere: Concentrate for solution for injection (20mg)

Detailed Information
Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

DOCETAXEL (doe se TAX el) is a chemotherapy drug. It targets fast dividing cells, like cancer cells, and causes these cells to die. This medicine is used to treat many types of cancers like breast cancer, certain stomach cancers, head and neck cancer, lung cancer, and prostate cancer.

In-Depth Information
Select a Medication

Taxotere 80mg/4ml Concentrate Solution for Injection

NDC: 000758004
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Breast Cancer, Gastric Cancer, Prostate Cancer, Non-small Cell Lung Cancer (NSCLC), Head And Neck Cancer

Sometimes used for but not FDA approved for the following conditions:
Malignant Melanoma, Ovarian Cancer

Storage Information
Protect from light
Store in carton until time of use
Store between 36 to 77 degrees F
Taxotere 80mg/4ml Concentrate Solution for Injection
Close All Sections Show

Reported Side Effects for Taxotere 80mg/4ml Concentrate Solution for Injection

Close Show
Acute Lung Injury Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Pulmonary Fibrosis Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Lung Inflammation Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Onycholysis Incidence:
0.8%*
Severity: MILD
Onset: DELAYED
Skin Rash Incidence:
1.0-10.0%*
Severity: MILD
Onset: EARLY
Low Platelet Count Incidence:
1.0-17.0%*
Severity: SEVERE
Onset: DELAYED
Fainting Incidence:
1.6-2.0%*
Severity: MILD
Onset: EARLY
Heart Failure Incidence:
2.3%*
Severity: SEVERE
Onset: DELAYED
Low Blood Pressure Incidence:
2.8%*
Severity: MODERATE
Onset: RAPID
Joint Pain Incidence:
3.0-9.0%*
Severity: MILD
Onset: DELAYED
Weakness Incidence:
4.4%*
Severity: MILD
Onset: EARLY
Conjunctivitis Incidence:
5.0%*
Severity: MODERATE
Onset: DELAYED
Epiphora Incidence:
>6.0%*
Severity: SEVERE
Onset: EARLY
Metallic Taste Incidence:
6.0%*
Severity: MILD
Onset: EARLY
Nose Bleed Incidence:
6.0%*
Severity: MILD
Onset: DELAYED
Muscle Pain Incidence:
6.0-21.0%*
Severity: MILD
Onset: EARLY
Infection Incidence:
6.0-33.0%*
Severity: SEVERE
Onset: DELAYED
Elevated Hepatic Enzymes Incidence:
7.3-18.9%*
Severity: MODERATE
Onset: DELAYED
Anemia Incidence:
8.0-31.0%*
Severity: SEVERE
Onset: DELAYED
High Bilirubin Level Incidence:
8.9%*
Severity: MODERATE
Onset: DELAYED
Swelling Incidence:
13.0-67.0%*
Severity: MODERATE
Onset: DELAYED
Shortness Of Breath Incidence:
15.0%*
Severity: MODERATE
Onset: EARLY
Mouth Ulcers Incidence:
19.0-67.0%*
Severity: MODERATE
Onset: DELAYED
Vomiting Incidence:
22.0-23.0%*
Severity: MILD
Onset: EARLY
Loose Stools Incidence:
23.0-43.0%*
Severity: MILD
Onset: EARLY
Fever Incidence:
31.0-41.0%*
Severity: MILD
Onset: EARLY
Low White Blood Cell Counts Incidence:
32.0-44.0%*
Severity: SEVERE
Onset: DELAYED
Upset Stomach Incidence:
34.0-42.0%*
Severity: MILD
Onset: EARLY
Weakness Incidence:
44.0-66.0%*
Severity: MILD
Onset: DELAYED
Hair Loss Incidence:
56.0-76.0%*
Severity: MILD
Onset: DELAYED
No Menstrual Periods Incidence:
62.0%*
Severity: MILD
Onset: DELAYED
Low White Blood Cells Incidence:
75.0-94.0%*
Severity: SEVERE
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
Close Show
FIRST Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

SECOND Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

THIRD Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Taxotere

Close Show

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5